Status:

TERMINATED

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

Lead Sponsor:

South Plains Oncology Consortium

Conditions:

Acute Myelogenous Leukemia

Acute Lymphoblastic Leukemia

Eligibility:

All Genders

Up to 21 years

Phase:

PHASE1

Brief Summary

The purposee of this study is to determine the safety and dosing of Fenretinide when given continuously for 5 days, every 3 weeks, in pediatric patients with recurrent and/or resistant acute lymphobla...

Detailed Description

Fenretinide is a cytotoxic retinoid that has activity against a variety of cell lines in vitro in a dose-related manner. The exact mechanism of fenretinide cytotoxicity in leukemia and lymphoma cell l...

Eligibility Criteria

Inclusion

  • Diagnosed with relapsed or refractory ALL, AML, or NHL
  • Must have had two or more therapeutic attempts for treating/curing disease
  • Must have fully recoved from acute toxic effects of all prior therapy
  • Karnofsky of greater than 50% for older than 10 years of age and Lansky greater than 50% for younger than 10 years.

Exclusion

  • Grade 2 Pruritus or Rash (all forms)
  • Grade 3 Dry Skin that is refractory to topical medical management
  • Cardiac Fractional Shortening \< 27% on echocardiogram
  • Left Ventricular Ejection Fraction \< 45% on echocardiogram
  • Known allergy to egg products or soy bean oil
  • Renal, Liver, and Pancreatic function:
  • serum creatinine \> 1.5X ULN
  • direct bilirubin \> 1.5X ULN
  • ALT or AST \> 2.5X ULN
  • Serum trigylcerides \> 2.5X ULN for age
  • Lipase \> 1.5X ULN for age
  • History of pancreatitis

Key Trial Info

Start Date :

August 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2018

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT01187810

Start Date

August 1 2010

End Date

April 1 2018

Last Update

March 31 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States, 73104

2

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | DecenTrialz